Sugatani T - Search Results

1

Early chronic kidney disease-mineral bone disorder stimulates vascular calcification.

Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Fang Y, et al. Among authors: sugatani t. Kidney Int. 2014 Jan;85(1):142-50. doi: 10.1038/ki.2013.271. Epub 2013 Jul 24. Kidney Int. 2014. PMID: 23884339 Free PMC article.

2

Cardiovascular risk factors in chronic kidney disease: does phosphate qualify?

Hruska K, Mathew S, Lund R, Fang Y, Sugatani T. Hruska K, et al. Among authors: sugatani t. Kidney Int Suppl. 2011 Apr;79(121):S9-13. doi: 10.1038/ki.2011.24. Epub 2011 Feb 23. Kidney Int Suppl. 2011. PMID: 21346719 Free PMC article. Review.

3

CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.

Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA. Fang Y, et al. Among authors: sugatani t. J Am Soc Nephrol. 2014 Aug;25(8):1760-73. doi: 10.1681/ASN.2013080818. Epub 2014 Feb 27. J Am Soc Nephrol. 2014. PMID: 24578135 Free PMC article. Clinical Trial.

4

Pathophysiology of the chronic kidney disease-mineral bone disorder.

Hruska KA, Seifert M, Sugatani T. Hruska KA, et al. Among authors: sugatani t. Curr Opin Nephrol Hypertens. 2015 Jul;24(4):303-9. doi: 10.1097/MNH.0000000000000132. Curr Opin Nephrol Hypertens. 2015. PMID: 26050115 Free PMC article. Review.

5

SIRT6 deficiency culminates in low-turnover osteopenia.

Sugatani T, Agapova O, Malluche HH, Hruska KA. Sugatani T, et al. Bone. 2015 Dec;81:168-177. doi: 10.1016/j.bone.2015.07.018. Epub 2015 Jul 17. Bone. 2015. PMID: 26189760 Free PMC article.

6

Cardiovascular risk factors in chronic kidney disease: does phosphate qualify?

Hruska K, Mathew S, Lund R, Fang Y, Sugatani T. Hruska K, et al. Among authors: sugatani t. Kidney Int. 2011 Apr;79121:S9-S13. doi: 10.1038/ki.2011.24. Kidney Int. 2011. PMID: 26746860 Free article. Review.

7

Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.

Agapova OA, Fang Y, Sugatani T, Seifert ME, Hruska KA. Agapova OA, et al. Among authors: sugatani t. Kidney Int. 2016 Jun;89(6):1231-43. doi: 10.1016/j.kint.2016.02.002. Epub 2016 Mar 11. Kidney Int. 2016. PMID: 27165838 Free PMC article.

8

Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

Sugatani T, Agapova OA, Fang Y, Berman AG, Wallace JM, Malluche HH, Faugere MC, Smith W, Sung V, Hruska KA. Sugatani T, et al. Kidney Int. 2017 Jan;91(1):86-95. doi: 10.1016/j.kint.2016.07.039. Epub 2016 Sep 22. Kidney Int. 2017. PMID: 27666759 Free PMC article.

9

The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.

Hruska KA, Sugatani T, Agapova O, Fang Y. Hruska KA, et al. Among authors: sugatani t. Bone. 2017 Jul;100:80-86. doi: 10.1016/j.bone.2017.01.023. Epub 2017 Jan 22. Bone. 2017. PMID: 28119179 Free PMC article. Review.

10

The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.

Williams MJ, Sugatani T, Agapova OA, Fang Y, Gaut JP, Faugere MC, Malluche HH, Hruska KA. Williams MJ, et al. Among authors: sugatani t. Kidney Int. 2018 Jan;93(1):147-158. doi: 10.1016/j.kint.2017.06.016. Epub 2017 Aug 23. Kidney Int. 2018. PMID: 28843411 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page